Case number 1:21-cv-00146
Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 1, 2022 | 21 | Other Document (3) Docket Text:Joint Quarterly Status Report ( Other Document ) filed by Mylan Pharmaceuticals Inc.. (O'Brien, William) |
| Apr 19, 2022 | 20 | Order (2) Docket Text:ORDER SCHEDULING STATUS REPORTS. The Court DIRECTS the parties to file a quarterly status report on the first of each March 2022, June 2022, September 2022, and December 2022, until this matter reaches resolution, the first of which shall be filed by June 1, 2022. Signed by Chief District Judge Thomas S Kleeh on 4/19/2022. (dk) |
| Apr 5, 2022 | N/A | Case Transferred Out to Another District (0) Docket Text: Case transferred to District of Delaware re MDL 2930. Entire Case file electronically transmitted. (dk) |
| Apr 5, 2022 | N/A | Case Transfer Complete (0) Docket Text: Case Transfer Complete - Case transferred to District of Delaware on 4/5/2022. District of Delaware's case number is 1:22-cv-00451. (dk) |
| Apr 5, 2022 | 19 | Other Document (2) Docket Text: CERTIFIED COPY OF JPML CONDITIONAL TRANSFER ORDER (CTO-1) re: pldg. ([82] in MDL No. 2930, 1 in WVN/1:21-cv-00146) transferring 1 action to the District of Delaware to be assigned to Honorable Richard G. Andrews. Inasmuch as no objection is pending at this time, the stay is lifted. Signed by Clerk of the Panel John W. Nichols on 4/5/2022. Associated Cases: MDL No. 2930, WVN/1:21-cv-00146. (dk) |
| Apr 1, 2022 | 17 | Stipulation and Order (3) Docket Text:STIPULATION AND ORDER dismissing Mylan, Inc., Mylan Laboratories Limited, and Viatris, Inc., without prejudice. Signed by Chief District Judge Thomas S Kleeh on 4/1/2022. (dk) |
| Apr 1, 2022 | 18 | Report of Rule 26(f) Planning Meeting (5) Docket Text: REPORT of Rule 26(f) Planning Meeting. (Copland, Gordon) |
| Mar 31, 2022 | 16 | Stipulation (4) Docket Text: STIPULATION and proposed order dismiss certain defendants by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Copland, Gordon) |
| Mar 24, 2022 | 14 | Corporate Disclosure Statement (3) Docket Text: Corporate Disclosure Statement by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. identifying Corporate Parent Mylan Inc. for Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.; Corporate Parent Viatris Inc. for Mylan Inc... (Copland, Gordon) |
| Mar 24, 2022 | 15 | Answer to Complaint (22) Docket Text:Defendants' ANSWER to [1] Complaint and Mylan Pharaceuticals', COUNTERCLAIM agaubst Bivartus against Mylan Pharmaceuticals Inc. by Mylan Pharmaceuticals Inc., Viatris Inc., Mylan Laboratories Limited, Mylan Inc..(Copland, Gordon) |
| Feb 25, 2022 | 10 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE Returned Executed by Novartis Pharmaceuticals Corporation. Mylan Pharmaceuticals Inc. waiver sent on 2/16/2022, answer due 4/18/2022. (Companion, James) |
| Feb 25, 2022 | 11 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE Returned Executed by Novartis Pharmaceuticals Corporation. Mylan Inc. waiver sent on 2/16/2022, answer due 4/18/2022. (Companion, James) |
| Feb 25, 2022 | 12 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE Returned Executed by Novartis Pharmaceuticals Corporation. Mylan Laboratories Limited waiver sent on 2/16/2022, answer due 4/18/2022. (Companion, James) |
| Feb 25, 2022 | 13 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE Returned Executed by Novartis Pharmaceuticals Corporation. Viatris Inc. waiver sent on 2/16/2022, answer due 4/18/2022. (Companion, James) |
| Feb 22, 2022 | 9 | FirstOrder (5) Docket Text:FIRST ORDER AND NOTICE REGARDING DISCOVERY AND SCHEDULING: ***NOTICE TO ATTORNEYS*** : Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, ALL Non-governmental CORPORATE parties must file a DISCLOSURE STATEMENT with the Court. Forms are available on the Court's Web Site at http://www.wvnd.uscourts.gov/forms.htm Rule 26 Meeting to be held by 3/18/2022. Rule 26 Meeting Report due by 4/1/2022. Discovery due by 4/18/2022. Signed by District Judge Thomas S. Kleeh on 2/22/2022. (dk) |
| Feb 17, 2022 | 8 | Notice of Appearance (2) Docket Text: NOTICE of Appearance by Gordon H. Copland on behalf of Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. (Copland, Gordon) |
| Jan 24, 2022 | 7 | Order Reassigning Case (1) Docket Text:ORDER. The Court ORDERS that the above-styled civil action be transferred to and placed on the docket of the Honorable Thomas S. Kleeh, District Judge. Senior Judge Irene M. Keeley no longer assigned to case. Signed by Senior Judge Irene M. Keeley on 1/24/2022. (dk) |
| Dec 20, 2021 | 1 | Main Document (14) Docket Text: COMPLAINT against All Defendants, filed by Novartis Pharmaceuticals Corporation. Filing Fee $402.00. Receipt No. AWVNDC-3393348. (Attachments: # (1) Exhibit A - U.S. Patent, # (2) Civil Cover Sheet) (dk) |
| Dec 20, 2021 | 1 | Exhibit A - U.S. Patent (16) |
| Dec 20, 2021 | 1 | Civil Cover Sheet (2) |
| Dec 20, 2021 | 2 | Notice of Verification of Attorney Admission (1) Docket Text: VERIFICATION OF ATTORNEY ADMISSION re [1] Complaint to Nicholas Kallas, Christina Schwarz, Christopher Loh, and Jared Stringham. (dk) |
| Dec 20, 2021 | 3 | Other Document (2) Docket Text:PLAINTIFF'S RULE 7.1 DISCLOSURE STATEMENT Other Document filed by Novartis Pharmaceuticals Corporation. (Companion, James) |
| Dec 20, 2021 | 4 | Other Document (2) Docket Text:PLAINTIFF'S SUPPLEMENTAL ANDA Other Document filed by Novartis Pharmaceuticals Corporation. (Companion, James) |
| Dec 20, 2021 | 5 | Other Document (1) Docket Text:REPORT TO USPTO Other Document filed by Novartis Pharmaceuticals Corporation. (Companion, James) |
| Dec 20, 2021 | 6 | Report Re: Patent/Trademark (1) Docket Text: REPORT to USPTO on the filing or determination of an action regarding re [1] Complaint. (dk) |
